Patent · US Active

PCSK9 antagonist compounds

US12209145B2 · kind B2 · utility

0Cited by
6References
29Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 30, 2022
Grant dateJan 28, 2025
Priority date—
Expiry dateJun 30, 2042

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are compounds of Formula I, or a salt thereof:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.